Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

Neurology

Volumn 76, Issue 22, 2011, Pages 1858-1865

  O'Connor, P W ^a   Goodman, A ^b   Kappos, L ^c   Lublin, F D ^d   Miller, D H ^e   Polman, C ^f   Rudick, R A ^g   Aschenbach, W ^h   Lucas, N ^h  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g LERNER RESEARCH INSTITUTE   (United States)

^h BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE;

EID: 79958137883     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821e7c8a     Document Type: Article

References (16)

1. Yousry TA, Habil M, Major EO, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933.
2. Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010;68:409-413.
3. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
4. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-4 integrin antibody on brain lesion activity in MS. Neurology 1999;53:466-472.
5. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-191.
6. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23. (Pubitemid 36026342)
7. Stüve O, Cravens P, Frohman E, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009;72:396-401.
8. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374. (Pubitemid 41132341)
9. Langer-Gould A, Atlas S, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381. (Pubitemid 41132342)
10. Polman CH, O'Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
11. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1 for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
12. Goodman AD, Rossman HS, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, doubleblind, placebo-controlled study. Neurology 2009;72: 806-812.
13. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumabtreated patients. Neurology 2008;70:1150-1151. (Pubitemid 351464749)
14. TYSABRI® (natalizumab) package insert. Cambridge, MA: Biogen Idec Inc.; 2008.
15. Niino M, Bodner C, Simard M-L, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59:748-754. (Pubitemid 43673152)
16. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747. (Pubitemid 43673151)